kinesin family member 22Genealiases: A-328A3.2 · KID · KNSL4 · OBP · OBP-1 · OBP-2
Q-omics provides the consensus-scored KIF22 profile across patient tissues and cancer cell-line models. KIF22 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KIF22 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, KIF22 protein abundance shows 31,506 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where KIF22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF22 survival associations across molecular data types. KIF22 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF22 RNA expression–survival associations across cancer types. High KIF22 expression shows unfavorable associations in ACC, KIRC, LIHC, MESO and SARC, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KIF22 RNA expression.
This table summarizes KIF22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF22 shows higher tumor expression in HNSC, BLCA, KIRP, KIRC, STAD and LIHC. The HNSC box plot shows higher KIF22 RNA expression in tumor versus normal tissue (log2 FC = +1.427, t-test p < 0.001).
This table shows molecular features associated with KIF22 in patient tissues and cancer cell lines. In patient samples, KIF22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
